ImageneBio Q3 net loss narrows as expenses fall
IMA•ImageneBio reported a Q3 net loss of $15.62 million and operating expenses of $17.31 million, with research and development and general and administrative expenses down year over year. It ended the quarter with $126.6 million in cash and expects funding to last into Q1 2028.
1. Quarterly results
ImageneBio said its Q3 net loss narrowed from a year earlier as research and development and general and administrative expenses declined. The company reported a net loss of $15.62 million and operating expenses of $17.31 million.
2. Cash outlook
ImageneBio ended Q3 with $126.6 million in cash and expects the funds to support operations into Q1 2028.
